Key points from article :
Cleara Biotech, set to accelerate FOXO4-therapeutics pipeline for niche-directed, anti-senescent lead candidates.
The company has announced that it closed a $2.5 million seed financing round earlier in the year, led by Apollo Health Ventures.
Cleara has optimised two lead developmental candidates, CL04177 and CL04183.
These can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans.
Aiming at precision medicine tools that treat specific diseases with clear niche-directed, anti-senescent lead candidates.
This will be accompanied by associated biomarkers, around its FOXO4-based D-amino acid peptides and pipeline against subtypes of senescence.
Designed and optimised based on an extensive 3D-structural, molecular and cellular understanding of cell scarring’s mechanism of action.
“As Cleara’s vision is to develop ... the Company’s pipeline and advancing our preclinical studies,” said Dr Peter de Keizer, Managing Director and Scientific Founder.
